Reduction in CV events seen with fish oil derivative in REDUCE-IT.
The use of empagliflozin in routine care of East Asian patients with type 2 diabetes reduced risk of hospitalization for heart failure, cardiovascular outcomes, and all-cause mortality vs DPP-4 inhibitors.
Addition of cardiac rehabilitation to usual care significantly improved QoL, functional capacity, and diastolic function in patients with HFpEF.
In patients with heart failure, sGC stimulators reduced risk of a combined endpoint including cardiovascular death and hospitalization for heart failure in individuals with reduced ejection fraction but had no benefit in those with preserved ejection fraction.
Data from the Swedish HF Registry show that the effect of beta-blockers in patients with HF With Preserved EF is unclear.
In meta-analysis of 62 placebo-controlled RCTs, SGLT2 inhibitors were associated with increased risk of infection and diabetic ketoacidosis but showed similar rates of hypoglycemia, bone fracture, and amputations as placebo.
In meta-analysis of 15 randomized, placebo-controlled clinical trials, SGLT2 inhibitors reduced risk of all-cause and CV mortality and risk of composite heart failure endpoint in key patient subgroups.
In meta-analysis of 8 randomized placebo-controlled clinical trials, addition of oral sGC stimulators to guideline-directed medical therapy for heart failure reduced risk of hospitalization for heart failure vs placebo; net adverse events not significantly increased over placebo.